Intuitive Surgical Inc (ISRG) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Intuitive Surgical Inc (ISRG) has a cash flow conversion efficiency ratio of 0.052x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($911.90 Million) by net assets ($17.60 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See ISRG net asset quality score to measure how much of total assets are equity-financed.
Intuitive Surgical Inc - Cash Flow Conversion Efficiency Trend (1999–2025)
This chart illustrates how Intuitive Surgical Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check ISRG cash flow quality score to evaluate the quality of earnings relative to operating cash generation.
Intuitive Surgical Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Intuitive Surgical Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
PDD Holdings Inc.
NASDAQ:PDD
|
0.110x |
|
SIEMENS ENERGY AG ADR/1
F:ENR0
|
0.272x |
|
SCHNEIDER ELECTR.ADR/1/5
F:SNDB
|
N/A |
|
Prologis Inc
NYSE:PLD
|
0.025x |
|
Rio Tinto Group
F:RIOA
|
0.042x |
|
Stryker Corporation
NYSE:SYK
|
0.096x |
|
Chubb Ltd
NYSE:CB
|
0.049x |
|
S&P Global Inc
NYSE:SPGI
|
0.048x |
Annual Cash Flow Conversion Efficiency for Intuitive Surgical Inc (1999–2025)
The table below shows the annual cash flow conversion efficiency of Intuitive Surgical Inc from 1999 to 2025. For the full company profile with market capitalisation and key ratios, see ISRG company net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $17.94 Billion | $3.03 Billion | 0.169x | +15.61% |
| 2024-12-31 | $16.53 Billion | $2.42 Billion | 0.146x | +7.92% |
| 2023-12-31 | $13.40 Billion | $1.81 Billion | 0.135x | +0.92% |
| 2022-12-31 | $11.11 Billion | $1.49 Billion | 0.134x | -23.26% |
| 2021-12-31 | $11.95 Billion | $2.09 Billion | 0.175x | +14.91% |
| 2020-12-31 | $9.76 Billion | $1.48 Billion | 0.152x | -21.13% |
| 2019-12-31 | $8.28 Billion | $1.60 Billion | 0.193x | +10.30% |
| 2018-12-31 | $6.69 Billion | $1.17 Billion | 0.175x | -27.73% |
| 2017-12-31 | $4.73 Billion | $1.14 Billion | 0.242x | +34.07% |
| 2016-12-31 | $5.78 Billion | $1.04 Billion | 0.181x | +1.01% |
| 2015-12-31 | $4.32 Billion | $771.90 Million | 0.179x | -9.20% |
| 2014-12-31 | $3.38 Billion | $665.10 Million | 0.197x | -21.69% |
| 2013-12-31 | $3.50 Billion | $880.00 Million | 0.251x | +10.51% |
| 2012-12-31 | $3.58 Billion | $814.20 Million | 0.227x | -11.21% |
| 2011-12-31 | $2.65 Billion | $677.60 Million | 0.256x | -1.17% |
| 2010-12-31 | $2.04 Billion | $528.00 Million | 0.259x | +3.46% |
| 2009-12-31 | $1.54 Billion | $385.06 Million | 0.250x | +14.04% |
| 2008-12-31 | $1.27 Billion | $278.24 Million | 0.220x | -5.10% |
| 2007-12-31 | $888.67 Million | $205.69 Million | 0.231x | +36.70% |
| 2006-12-31 | $589.71 Million | $99.84 Million | 0.169x | +5.86% |
| 2005-12-31 | $442.59 Million | $70.79 Million | 0.160x | +66.15% |
| 2004-12-31 | $314.93 Million | $30.32 Million | 0.096x | +441.89% |
| 2003-12-31 | $278.96 Million | $-7.85 Million | -0.028x | +87.33% |
| 2002-12-31 | $63.68 Million | $-14.15 Million | -0.222x | +6.24% |
| 2001-12-31 | $78.29 Million | $-18.55 Million | -0.237x | -67.92% |
| 2000-12-31 | $90.73 Million | $-12.80 Million | -0.141x | +80.32% |
| 1999-12-31 | $22.21 Million | $-15.93 Million | -0.717x | -- |
About Intuitive Surgical Inc
Intuitive Surgical, Inc. develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. It offers the da Vinci Surgical System that enables surgical procedures using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings… Read more